However, viral infection can dramatically increase the resistance to exogenous EPO administration, as already shown during other inflammatory conditions [25,26,27]; for this reason, the evaluation of the erythropoietin resistance index (ERI) should be considered in weighing risks and benefits of EPO administration to COVID-19 patients. Here, EPO is linked to COVID-19.